Quanterix

Life Sciences Challenges Will Limit Prospects But Synergies Will Aid

AnalystLowTarget

Not Invested

Community Contributor

Published

09 Aug 25

AnalystLowTarget's Fair Value

US$5.00

21.6% overvalued

04 Sep

US$6.08

-46.4%

15.8%

-46.4%

15.8%

You can edit this narrative until Aug 9 10:23 PM. Then, changes will post as Updates.

Author's Valuation

US$521.6% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$5

21.6% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

16.51%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.51%

Calculation

US$45.84m

Earnings '28

11.04x

PE Ratio '28

US$506.07m

Market Cap '28

US$506.07m

Market Cap '28

81.53m

No. shares '28

US$6.21

Share Price '28

US$6.21 Share Price '28

Discounted to 2025 @ 7.48% p.a.

US$5.00

Fair Value '25